2026-06722NoticeWallet

FDA Hands Fast-Track Voucher to Rare Kids' Disease Drug Maker

Published Date: 4/7/2026

Notice

Summary

The FDA just gave a special fast-track ticket called a Priority Review Voucher to Immedica Pharma AB for their rare pediatric disease drug, LOARGYS, approved in February 2026. This voucher lets the company speed up the review of another medicine in the future, helping kids with rare diseases get treatments faster. It’s a big win for patients, the company, and anyone watching rare disease drug development!

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

LOARGYS approved for ARG1‑D patients

The FDA approved LOARGYS (pegzilarginase-nbln) on February 23, 2026. LOARGYS injection is indicated to treat hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1‑D), to be used with dietary protein restriction.

FDA issues Rare Pediatric Priority Review Voucher

The FDA announced it issued a priority review voucher to the sponsor, Immedica Pharma AB, for the approved rare pediatric disease product LOARGYS (approved February 23, 2026). The issuance was made under section 529 of the Federal Food, Drug, and Cosmetic Act.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
4/7/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register